GENFIT S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 USD | -1.11% |
|
+5.45% | +15.58% |
| Sales 2024 * | 82.48M 89.95M | Sales 2025 * | 48.49M 52.88M | Capitalization | 209M 228M |
|---|---|---|---|---|---|
| Net income 2024 * | 28M 30.54M | Net income 2025 * | -22M -23.99M | EV / Sales 2024 * | 2.52 x |
| Net cash position 2024 * | 1.26M 1.37M | Net cash position 2025 * | 32.5M 35.44M | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
8.24
x | P/E ratio 2025 * |
-29
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genfit S.A.
More recommendations
More press releases
More news
| 1 day | -1.11% | ||
| 1 week | +5.45% | ||
| Current month | +23.27% | ||
| 1 month | +8.80% | ||
| 3 months | +22.59% | ||
| 6 months | +28.80% | ||
| Current year | +15.58% |
1 week
4.20
4.53
1 month
3.614.53
Current year
3.316.05
1 year
2.896.05
3 years
2.896.38
5 years
2.8922.48
10 years
2.8926.25
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
| Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 21-03-03 | |
| Founder | 68 | 99-08-31 | |
| Founder | 52 | 99-09-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 4.45 | -1.11% | 11,232 |
| 24-07-15 | 4.5 | +5.88% | 6,639 |
| 24-07-12 | 4.25 | -3.50% | 15,537 |
| 24-07-11 | 4.404 | +0.94% | 12,210 |
| 24-07-10 | 4.363 | +3.39% | 6,110 |
Delayed Quote Nasdaq, July 16, 2024 at 04:30 pm EDT
More quotes
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.
The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Calendar
2024-09-18
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.2
EUR
Average target price
9.325
EUR
Spread / Average Target
+122.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 47.96B | |
| +45.38% | 41.47B | |
| +0.69% | 42.45B | |
| +30.52% | 31.6B | |
| +22.30% | 28.63B | |
| -6.35% | 28.03B | |
| +49.25% | 14.56B | |
| +49.18% | 14.14B | |
| +3.45% | 12.58B |
- Stock Market
- Equities
- GNFT Stock
- GNFT Stock
